3-acetyl-1H-indole-6-carboxylic acid | 1105192-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-acetyl-1H-indole-6-carboxylic acid
• CAS: 1105192-45-7
• 化学式: C₁₁H₉NO₃
• 分子量: 203.19
• InChiKey: PSFFTDLDFVWLPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239919A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R 12 or R 13 on the A group is a carbamate, ester, or ketone substituent (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本文提供了包含式I的补体因子D抑制剂的化合物、使用方法和制备方法，或其药学上可接受的盐或组合物，其中A基团上的R12或R13是一个氨基甲酸酯、酯或酮取代基（R32）。所述抑制剂靶向因子D，能够在替代补体途径的早期和关键点抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。这些因子D抑制剂能够减少过度激活补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10370394B2

  公开（公告）日：2019-08-06

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is a carbamate, ester, or ketone substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本发明提供了包含式 I 或其药学上可接受的盐或组合物的补体因子 D 抑制剂的化合物、使用方法和制造工艺，其中 A 基上的 R12 或 R13 是氨基甲酸酯、酯或酮取代基 (R32)。本文所述的抑制剂以因子 D 为靶点，在替代补体途径的早期和关键点抑制或调节补体级联，并降低因子 D 调节经典和凝集素补体途径的能力。本文所述的因子 D 抑制剂能够减少补体的过度活化，而补体的过度活化与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：EP3110804A1

  公开（公告）日：2017-01-04
• US9732103B2
  申请人：——

  公开号：US9732103B2

  公开（公告）日：2017-08-15
• [EN] CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS DE CARBAMATE, D'ESTER, ET DE CÉTONE POUR LE TRAITEMENT DES TROUBLES MÉDIÉS PAR LE COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2015130830A9

  公开（公告）日：2016-06-23

  [EN] Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is a carbamate, ester, or ketone substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
  [FR] Cette invention concerne des composés, des procédés d'utilisation, et des procédés de production d'inhibiteurs du facteur D du complément comprenant la Formule I, ou un sel pharmaceutiquement acceptable de ceux-ci ou une composition les contenant, R12 ou R13 sur le groupe A étant un substituant carbamate, ester, ou cétone (R32). Les inhibiteurs ci-décrits ciblent le facteur D et inhibent ou régulent la cascade du complément en un point précoce et essentiel dans la voie alterne du complément, et réduisent la capacité du facteur D à moduler la voie classique du complément et la voie des lectines. Les inhibiteurs du facteur D ci-décrits sont capables de réduire l'activation excessive du complément, qui a été associée à certaines maladies auto-immunes, inflammatoires, et neurodégénératives, ainsi qu'à la lésion de reperfusion post-ischémique et au cancer.